A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 117-124

  Das, Vidya Nand Rabi ^a   Siddiqui, Niyamat Ali ^a   Pandey, Krishna ^a   Singh, Vijay Pratap ^a   Topno, Roshan K ^a   Singh, Dharmendra ^a   Verma, Rakesh Bihari ^a   Ranjan, Alok ^a   Sinha, Prabhat Kumar ^a   Das, Pradeep ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Amphotericin B deoxycholate; Apparent cure rate; Relapse rate; Sodium stibogluconate; Ultimate cure rate

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; PENTAMIDINE; STIBOGLUCONATE SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DRUG CHOICE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INDIA; MALE; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SIDE EFFECT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS;

EID: 77949440889     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother. 2001;45:2185-2197.
2. Guerin P, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494-501.
3. Arias JR, Monteiro PS, Zicker F. The re-emergence of visceral leishmaniasis in Brazil. Emerg Infect Dis. 1996;2:145-146.
4. Ranjan A, Sur Dipika Singh VP, Siddiqui NA, et al. Risk factors for Indian Kala-azar. Am J Trop Med Hyg. 2005;73:74-78.
5. Sundar S, More DK, Singh MK, et al. Failure of Pentavalent antimony in visceral leishmaniasis in India: report from the center of Indian epidemic. Clin Infect Dis. 2000;31:1104-1106.
6. Thakur CP, Narayan S. A comparative evaluation of Amphotericin B and Sodium Antimony Gluconate, as first line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol. 2004;98:129-138.
7. Das VNR, Ranjan A, Bimal S, et al. Magnitude of unresponsiveness to Sodium-Stibo-Gluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India. 2005;18:131-133.
8. Mishra M, Biswas UK, Jha AM, Khan AB. Amphoterocin B versus Pentamidine in antimony-unresponsive Kala-azar cases. Lancet. 1992;340:1256-1257.
9. Das VNR, Ranjan A, Sinha AN, et al. A randomised clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India. 2001;49:609-612.
10. Olliaro PL, Guerin PJ, Gersti S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005;5:763-774.
11. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111-126.
12. Sundar S, Chatterjee M. Visceral Leishmaniasis- current therapeutic modalities. Indian J Med Res. 2006;123:345-352.
13. Berman JD. Human Leishmaniasis: clinical, diagnostic and chemotherapeutic development in the last 10 years. Clin Infect Dis. 1997;24:684-703.
14. Murray HW. Treatment of visceral leishmaniasis (Kala-azar): a decade of progress and future approaches. Int J Infect Dis. 2000;4:158-177.
15. Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today. 1993;9:323-328.
16. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007;196:591-598.
17. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibo-gluconate in first line treatment of Indian Kala-azar. Lancet. 1994;344:1599-1600.
18. Thakur CP, Sinha SP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation on Amphotericin B as a first line drug in comparison to Stibo-Gluconate in the treatment of fresh cases of Kala-azar. Indian J Med Res. 1993;97:170-175.
19. Thakur CP, Kumar P, Kumar N, Singh GN, Kumar A, Narayan S. A randomised comparison of classical mode of Amphotericin B with its newer modes of administration in Kala-azar. J Assoc Physicians India. 1998;46:762-765.
20. Thakur CP. A single high dose treatment of Kala-azar with Ambisome (Amphotericin B Lipid complex): a pilot study. Int J Antimicrob Agents. 2001;17:67-70.
21. Bernard E, Quaranta JF, Durant J, Le Fichous Y, Dellamonica P. Visceral Leishmaniasis resistant to conventional treatments: value of Amphotericine B. Pathol Biol (Paris). 1993;41(8 Pt. 2):817-819.
22. Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: Response to 15 daily versus alternate day infusions. Clin Infect Dis. 2007;45:556-561.
23. Sundar S. Management of Kala-azar in India: Current Concepts. 2005. Cited Oct 10, 2008. Available from: http://medind.nic.in/imvw/imvw6472.html.
24. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999;93:319-323.
25. Tabatabaie P, Saidati A, Khotaii G, Manishi S. Successful treatment with amphotericin B of patients with visceral Leishmaniasis resistant to meglumine antimonite. Acta Medica Iranica. 2004;42:61-64.
26. Vanlerberghe V, Diap G, Guerin PJ, et al. Drug policy for visceral Leishmaniasis: a cost effectiveness analysis. Trop Med Int Health. 2007;12:274-283.
27. Thakur CP, Sinha GP, Pandey AK, et al. Do the diminishing efficacy and increasing toxicity of SSG, in the treatment of Kala-azar in Bihar, India, justify its continued use. Ann Trop Med Parasitol. 1998;92:561-569.
28. Sundar S, Mehta H, Suresh AB, Singh P, Murray HW. Amphotericin B treatment for Indian Visceral Leishmaniasis: conventional verses lipid formulation. Clin Infect Dis. 2004;38:377-383.
29. Jha TK. Evaluation of Pentamidine isethionate in the treatment of Kala-azar occurring in North-Bihar, India. Trans R Soc Trop Med Hyg. 1983;77:167-170.
30. Sinha AN, Sinha SP, Sen AB, Saran R. Unresponsiveness in Indian Kala-azar. Indian J Parasitol. 1994;18:7-12.
31. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal Amphotericin B: randomized trial. Br Med J. 2001;323:419-422.
32. Thakur CP, Kumar MM, Pandey AK. Comparisons of regimens of treatment of resistant Kala-azar patients: A randomised study. Am J Trop Med Hyg. 1991;45:435-440.
33. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med. 2003;49:61-68.
34. Thakur CP, Sinha GP, Sharma V, Barat D. Treatment of Kala-azar during pregnancy. Natl Med J India. 1993;6:263-265.
35. Giri OP. Treatment of Visceral Leishmaniasis unresponsive to Pentamidine with Amphotericin B. J Assoc Physicians India. 1994;42:688-689.
36. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian leishmaniasis. N Engl J Med. 2002;347:1739-1746.